Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the marketing of its chemical substance drug, Pentazocine, marking it as the third enterprise in China to gain such approval. This development signals a significant milestone for the company in the competitive pharmaceutical industry, potentially impacting its market performance positively.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
